Manchester Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$427K Buy
11,611
+6,697
+136% +$317K 0.06% 184
2025
Q4
$250K Sell
4,914
-2,271
-32% -$116K 0.03% 245
2025
Q3
$399K Buy
7,185
+1,637
+30% +$95.8K 0.05% 228
2025
Q2
$383K Buy
5,548
+98
+2% +$6.67K 0.05% 253
2025
Q1
$378K Sell
5,450
-1
-0% -$83 0.05% 247
2024
Q4
$469K Sell
5,451
-3,260
-37% -$353K 0.05% 207
2024
Q3
$1.04M Sell
8,711
-3,262
-27% -$435K 0.12% 115
2024
Q2
$1.71M Hold
11,973
0.21% 68
2024
Q1
$1.54M Buy
11,973
+4,528
+61% +$539K 0.19% 80
2023
Q4
$770K Buy
7,445
+1,759
+31% +$174K 0.1% 124
2023
Q3
$517K Buy
5,686
+5,414
+1,990% +$477K 0.08% 152
2023
Q2
$22K Hold
272
﹤0.01% 491
2023
Q1
$21.6K Hold
272
﹤0.01% 492
2022
Q4
$18.4K Hold
272
﹤0.01% 418
2022
Q3
$14K Hold
272
﹤0.01% 432
2022
Q2
$15K Hold
272
﹤0.01% 443
2022
Q1
$15K Sell
272
-196
-42% -$10.1K ﹤0.01% 497
2021
Q4
$26K Sell
468
-560
-54% -$30.3K ﹤0.01% 455
2021
Q3
$49K Sell
1,028
-270
-21% -$13.1K 0.01% 431
2021
Q2
$54K Buy
1,298
+466
+56% +$18.1K 0.01% 379
2021
Q1
$28K Hold
832
﹤0.01% 421
2020
Q4
$29K Buy
+832
New +$28.8K ﹤0.01% 406
2015
Q1
Sell
-5,864
Closed -$124K 762
2014
Q4
$124K Sell
5,864
-2,930
-33% -$65.4K 0.02% 491
2014
Q3
$209K Buy
8,794
+720
+9% +$16.6K 0.03% 341
2014
Q2
$186K Buy
+8,074
New +$178K 0.02% 382
2013
Q4
Sell
-2,710
Closed -$46K 949
2013
Q3
$46K Hold
2,710
0.01% 617
2013
Q2
$42K Buy
+2,710
New +$45.1K 0.01% 635

Other funds holding NVO

Manchester Capital Management's NVO Position: Q1 2026 in Review

Manchester Capital Management increased its Novo Nordisk (NVO) stake by 136% in Q1 2026, buying an estimated $317K and bringing the position to 11,611 shares worth $427K. The position accounts for 0.06% of the portfolio, ranked #184.

Manchester Capital Management first reported a position in NVO in Q2 2013 and has held it in 27 quarters since. The position peaked at $1.71M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Manchester Capital Management held 11,611 shares of Novo Nordisk worth $427K as of Q1 2026.
  • Manchester Capital Management bought 6,697 Novo Nordisk shares in Q1 2026, an estimated $317K.
  • Novo Nordisk made up 0.06% of Manchester Capital Management's portfolio in Q1 2026, its #184 holding.
  • Manchester Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 27 quarters since.
  • Manchester Capital Management's Novo Nordisk position peaked at $1.71M in Q2 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.